Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT ...

B-cells and Antibodies – B-cells make antibodies, which help your body recognise and fight infections. Smoking reduces the ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

In the current study, the scientists thought NK cells might also have a direct impact on the brain chemicals that modulate ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the upcoming ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting ...

Clear signs of immune activation: ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune ...

As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated ...

Fintel reports that on May 20, 2025, Piper Sandler upgraded their outlook for ImmunityBio (NasdaqGS:IBRX) from Neutral to ...

Detailed price information for Mink Therapeutics Inc (INKT-Q) from The Globe and Mail including charting and trades.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...